ATP6AP2
Renin receptor
Also known as: APT6M8-9, ATP6IP2, ATP6M8-9, M8-9, PRR, RENR, RENR_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O75787
- Gene
- ATP6AP2
- Ensembl
- ENSG00000182220
- Chromosome
- X
- Canonical length
- 350 aa
- Protein class
- Disease related genes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters
OverviewNCBI Gene
This gene encodes a protein that is associated with adenosine triphosphatases (ATPases). Proton-translocating ATPases have fundamental roles in energy conservation, secondary active transport, acidification of intracellular compartments, and cellular pH homeostasis. There are three classes of ATPases- F, P, and V. The vacuolar (V-type) ATPases have a transmembrane proton-conducting sector and an extramembrane catalytic sector. The encoded protein has been found associated with the transmembrane sector of the V-type ATPases. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
350 residues, UniProt reviewed canonical sequence.
>O75787|ATP6AP2
1 MAVFVVLLAL VAGVLGNEFS ILKSPGSVVF RNGNWPIPGE RIPDVAALSM GFSVKEDLSW
61 PGLAVGNLFH RPRATVMVMV KGVNKLALPP GSVISYPLEN AVPFSLDSVA NSIHSLFSEE
121 TPVVLQLAPS EERVYMVGKA NSVFEDLSVT LRQLRNRLFQ ENSVLSSLPL NSLSRNNEVD
181 LLFLSELQVL HDISSLLSRH KHLAKDHSPD LYSLELAGLD EIGKRYGEDS EQFRDASKIL
241 VDALQKFADD MYSLYGGNAV VELVTVKSFD TSLIRKTRTI LEAKQAKNPA SPYNLAYKYN
301 FEYSVVFNMV LWIMIALALA VIITSYNIWN MDPGYDSIIY RMTNQKIRMDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ATP6AP2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.34
- Highest tissue expression
- 719 nTPM
Expression across tissuesHPA
Tissue
- parathyroid gland: 719 nTPM
- thyroid gland: 166 nTPM
- kidney: 155 nTPM
- bone marrow: 117 nTPM
- smooth muscle: 117 nTPM
- cerebral cortex: 109 nTPM
Single-cell type
- hofbauer cells: 1,185 nCPM
- epididymal clear cells: 455 nCPM
- kupffer cells: 417 nCPM
- decidual stromal cells: 327 nCPM
- respiratory ionocytes: 305 nCPM
- esophageal apical cells: 305 nCPM
Immune cell
- total PBMC: 694 nTPM
- classical monocyte: 513 nTPM
- eosinophil: 406 nTPM
- non-classical monocyte: 381 nTPM
- intermediate monocyte: 366 nTPM
- myeloid DC: 342 nTPM
Brain region
- white matter: 140 nTPM
- cerebral cortex: 124 nTPM
- hypothalamus: 122 nTPM
- thalamus: 115 nTPM
- basal ganglia: 110 nTPM
- spinal cord: 109 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about ATP6AP2.
Disease | AllUniProt
Conditions ATP6AP2 is implicated in, by any mechanism.
- Intellectual developmental disorder, X-linked, syndromic, Hedera type (MRXSH) MIM:300423
- Parkinsonism with spasticity, X-linked (XPDS) MIM:300911
- Congenital disorder of glycosylation 2R (CDG2R) MIM:301045
Disease | GeneticClinVar
6 pathogenic / likely-pathogenic of 356 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Syndromic X-linked intellectual disability Hedera type
- X-linked parkinsonism-spasticity syndrome
- Congenital disorder of glycosylation, type IIr
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.43
- gnomAD pLI
- 0.87
- gnomAD missense Z
- 1.66
- DepMap mean gene effect
- -0.72
- DepMap dependency class
- common
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- angiotensin maturation
- central nervous system maturation
- endosomal lumen acidification
- Golgi lumen acidification
- head morphogenesis
- intracellular pH reduction
- lysosomal lumen acidification
- positive regulation of canonical Wnt signaling pathway
- positive regulation of transforming growth factor beta1 production
- positive regulation of Wnt signaling pathway
- proton transmembrane transport
- regulation of MAPK cascade
- rostrocaudal neural tube patterning
- synaptic vesicle lumen acidification
- vacuolar acidification
- eye pigmentation
Molecular functions
Cellular components
- autophagosome membrane
- axon
- clathrin-coated vesicle membrane
- dendritic spine membrane
- endoplasmic reticulum membrane
- endosome membrane
- external side of plasma membrane
- extracellular exosome
- ficolin-1-rich granule membrane
- Golgi membrane
- lysosomal membrane
- lysosome
- membrane
- plasma membrane
- proton-transporting V-type ATPase complex
- synaptic vesicle membrane
- tertiary granule membrane
- vacuolar proton-transporting V-type ATPase complex
- vacuolar proton-transporting V-type ATPase, V0 domain
Protein domainsUniProt · Pfam · InterPro
- Renin receptor-like
- Renin receptor-like, C-terminal transmembrane spanning segment
- Renin receptor, N-terminal domain
- Renin receptor-like transmembrane spanning segment
- Renin receptor N-terminal domain
KeywordsUniProt
- Cell membrane
- Cell projection
- Cleavage on pair of basic residues
- Congenital disorder of glycosylation
- Cytoplasmic vesicle
- Endoplasmic reticulum
- Endosome
- Epilepsy
- Intellectual disability
- Lysosome
- Membrane
- Neurodegeneration
- Parkinsonism
- Phosphoprotein
- Postsynaptic cell membrane
- Receptor
- Signal
- Synapse
- Transmembrane
- Transmembrane helix
InteractionsUniProt · HPA
Protein binding partners of ATP6AP2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ATP6AP2 as an antibody target. Whether an autoantibody or antibody against ATP6AP2 could matter depends on whether native ATP6AP2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ATP6AP2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label ATP6AP2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...